Nature Medicine Review: AI Reconstructs the Paradigm of Drug Development
Release time:
2025-04-25
In the prolonged battle between humanity and disease, drug development remains the decisive battleground. Faced with the harsh reality of an average investment of $2.6 billion, a 15-year timeline, and a success rate below 10%, global scientists are turning to artificial intelligence (AI). This disruptive technology is quietly ushering drug development into a new era of "algorithm-driven" innovation. By 2025, the latest research in Nature journals reveals that generative AI models, exemplified by ChatGPT and Sora, are reshaping the entire drug development pipeline—from target discovery to clinical trials—accelerating "AI-driven drug discovery" from concept to clinical practice.
AI-Driven Intelligent Revolution in Core Drug Development Stages
1. Target Identification: Breaking Traditional Limits, Unleashing Data Value
Traditional small-molecule target identification methods are time-consuming, labor-intensive, and prone to failure. AI achieves breakthroughs by analyzing large datasets within complex biological networks, constructing multi-omics data networks to identify disease-related molecular patterns and causal relationships. Natural language processing (NLP) enhances sensitivity in target identification, while graph deep learning tackles data integration and model interpretability. Knowledge graphs combined with biomedical large language models (LLMs) uncover gene-disease pathway relationships. Despite challenges such as unstructured real-world data and lack of standardization, these datasets can still train effective models. Future integration of data mining and expert knowledge will further boost target discovery success rates.
2. Virtual Screening: Accelerating Lead Compound Identification
Virtual screening is critical for identifying potential lead compounds. Rapid expansion of compound libraries has driven advancements in AI-based ligand docking technologies. While models can predict ligand spatial transformations, issues persist, such as unrealistic conformations and limitations in surpassing physics-based methods. Sequence-based prediction struggles to capture 3D interaction complexity when target structures are missing. Phenotype-based virtual screening suits diseases with unknown targets but faces model generalization challenges. Current priorities include developing universal models, leveraging active learning, and integrating quantum mechanics and molecular dynamics simulations to enhance screening efficiency.
3. De Novo Design: Pioneering Automated Innovation
AI-powered de novo drug design automates the creation of novel chemical structures. Deep learning-driven molecular generators use chemical language or graph-based models. Chemical language models face "grammatical errors," while graph-based models require improvements in molecular validity and rationality. Introducing scoring functions and constraints (e.g., PocketFlow’s protein pocket-conditioned generation) guides models to produce bioactive compounds.
4. ADMET Prediction: Ensuring Efficacy and Safety
ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties are vital for drug viability. AI predicts ADMET using predefined features and deep learning, with neural network architectures playing key roles. Challenges include scarce labeled data and poor model interpretability. Emerging solutions involve unsupervised/self-supervised learning, multimodal models, and attention mechanisms.
5. Synthesis Planning & Automation: Overcoming Drug Synthesis Bottlenecks
Chemical synthesis remains a bottleneck in small-molecule drug discovery. AI-assisted synthesis planning has evolved from rule-based systems to deep learning models with improved interpretability. Automation combined with design-make-test-analyze (DMTA) cycles accelerates discovery but faces technical hurdles, such as minimizing solid formation and solubility prediction.
6. Clinical Trials & Real-World Applications: Optimizing End-to-End Development
AI excels in clinical and real-world settings. It aids biomarker discovery via digital pathology frameworks, optimizes pharmacodynamic predictions, supports personalized treatments, and drives drug repurposing. By analyzing multimodal data, AI enhances trial efficiency, outcome prediction, and patient recruitment. Despite data quality and interpretability challenges, AI continues to revolutionize drug discovery.
Challenges & Future Directions: Co-Evolution of Humans and Machines
While AI demonstrates immense potential, no AI-developed drug has yet reached Phase III trials, highlighting key challenges:
Data Limitations: Scarce high-quality training data due to costs, privacy laws, and sharing barriers, especially for rare diseases or novel targets. Existing datasets often suffer from incompleteness, errors, and biases.
Design Complexity: Balancing multi-objective optimization (e.g., druggability vs. chemical novelty) and the lack of standardized evaluation metrics.
Technical Hurdles: Molecular representation limitations, imprecise synthesis feasibility assessments, "undruggable" targets, and computational resource constraints.
Future Strategies:
Data Innovation: Foster data sharing, develop "sparse-data" algorithms, and integrate multimodal pre-trained models for drug repurposing.
Technical Synergy: Leverage multimodal fusion, GPU-powered big data, and emerging omics models.
Algorithm Optimization: Embed physical laws into models to reduce data dependency and improve accuracy.
Regulatory Compliance: Develop interpretable models to build trust and accelerate approvals.
Conclusion
From trial-and-error to computational mastery, AI is redefining the efficiency and strategic thinking of drug development. Each algorithmic iteration unlocks new possibilities for human health. When the first fully AI-designed drug reaches pharmacy shelves, it will mark not only a technological triumph but a radiant milestone in human ingenuity.
Latest developments
The debut and discourse of the YinFeng Life Continuation Project not only served as an authoritative demonstration of its own ethical governance framework but also contributed practical wisdom toward establishing industry norms.
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
